Top Markets
Coin of the day
AstraZeneca PLC AstraZeneca PLC

AstraZeneca PLC

AZN
Hisse Senetlerindeki Sıralama #105
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery,... AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Hisse Fiyatı
$193.62
Piyasa Değeri
$150.08B
Değişim (1 gün)
2.76%
Değişim (1 yıl)
184.69%
Ülke
GB
Ticaret AstraZeneca PLC (AZN)

Kategori

AstraZeneca PLC (AZN) için gelir
Dec 2025 itibarıyla gelir TTM: $58.74B
AstraZeneca PLC şirketinin en son finansal raporlarına göre, mevcut geliri (TTM) $58.74B'dir. 2024 yılında şirketin geliri $54.07B önceki yıla göre artış 2023 yılındaki $45.81B gelirine göre. Gelir, bir şirketin mal veya hizmet satışından elde ettiği toplam tutardır. Kazançtan farklı olarak, hiçbir gider düşülmez.
AstraZeneca PLC için 2000 ile 2026 arasındaki gelir geçmişi
Her yılın sonunda gelir
Yıl Gelir Değiştir
2026 (TTM) $58.74B 0.00%
2025 $58.74B 8.63%
2024 $54.07B 18.03%
2023 $45.81B 3.29%
2022 $44.35B 18.53%
2021 $37.42B 40.58%
2020 $26.62B 9.16%
2019 $24.38B 10.38%
2018 $22.09B -1.67%
2017 $22.47B -2.33%
2016 $23.00B -6.90%
2015 $24.71B -6.93%
2014 $26.55B 2.87%
2013 $25.81B -7.75%
2012 $27.97B -16.72%
2011 $33.59B 0.97%
2010 $33.27B 1.42%
2009 $32.80B 3.81%
2008 $31.60B 6.91%
2007 $29.56B 11.65%
2006 $26.48B 10.54%
2005 $23.95B 11.78%
2004 $21.43B 13.67%
2003 $18.85B 5.65%
2002 $17.84B 8.26%
2001 $16.48B -9.03%
2000 $18.12B 0.00%
Benzer şirketler veya rakiplerin geliri
Şirket Gelir Gelir Farkı Ülke
$65.18B 10.96%
US
$94.19B 60.36%
US
$61.16B 4.12%
US
$56.15B -4.41%
CH
$65.01B 10.68%
US